Select Publications
Journal articles
2006, '94', The Journal of Heart and Lung Transplantation, 25, pp. S76 - S76, http://dx.doi.org/10.1016/j.healun.2005.11.099
,2006, 'Apparent clearance of sirolimus in heart transplant recipients: Impact of primary diagnosis and serum lipids', Therapeutic Drug Monitoring, 28, pp. 614 - 622
,2006, 'Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease', Cardiology in the Young, 16, pp. 268 - 274
,2006, 'Comparsion and validation of three measures of quality of life in patients with pulmonary hypertension', Internal Medicine Journal, 36, pp. 705 - 710
,2006, 'Decision support tool to individualise cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclospoine C2 monitoring', Journal of Heart and Lung Transplantation, 25, pp. 1223 - 1229
,2006, 'Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing', Pharmacoeconomics, 24, pp. 903 - 915
,2006, 'Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: Results of a 12-month, single-blind, randomized, parallel-group, multicenter stud', Journal of Heart and Lung Transplantation, 25, pp. 935 - 941
,2005, 'A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients', Journal of Infectious Diseases, 192, pp. 1349 - 1354, http://dx.doi.org/10.1086/466532
,2005, 'Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures - A randomised controlled trial', Heart Lung and Circulation, 14, pp. 245 - 251, http://dx.doi.org/10.1016/j.hlc.2005.06.007
,2005, 'Ambrisentan therapy for pulmonary arterial hypertension', Journal of the American College of Cardiology, 46, pp. 529 - 535
,2005, 'Combining treprostinil and sildenafil in the treatment of pulmonary hypertension', Internal Medicine Journal, 35, pp. 684 - U3
,2005, 'Factors influencing dosing and concentrations of sirolimus in de novo heart transplant recipients', American Journal of Transplantation, 5, pp. 169 - 169
,2005, 'Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors', Transplantation Proceedings, 37, pp. 1 - 3, http://www.sciencedirect.com/science/article/B6VJ0-4FVHVB1-1/2/55a5e31d9b1b3e2b6a712cc8143bf698
,2005, 'Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension associated with connective tissue diseases', Arthritis Care & Research, 52, pp. S166 - S166
,2005, 'Long-term benefits of mycophenolate mofetil after heart transplantation', Transplantation, 79, pp. S45 - S46
,2005, 'Long-term sildenafil use lowers elevated transpulmonary gradients in NYHA class IV heart failure patients allowing successful heart transplantation', Journal of Cardiac Failure, 11, pp. S134 - S134
,2005, 'Novel use of sildenafil in the treatment of portopulmonary hypertension', Journal of Heart and Lung Transplantation, 24, pp. 498 - 500
,2005, 'P2X(1) receptors are closely associated with connexin 43 in human ventricular myocardium', International Journal of Cardiology, 98, pp. 291 - 297
,2005, 'Spinal Cord Stimulation Significantly Improves Refractory Angina Pectoris-A Local Experience: Spinal Cord Stimulation in Refractory Angina', Heart Lung and Circulation, 14, pp. 3 - 7, http://www.sciencedirect.com/science/article/B7CW2-4FJV22N-4/2/6b6b4c9181d27982bd0fab7cc4ec88f5
,2005, 'Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients', Journal of Heart and Lung Transplantation, 24, pp. 517 - 525
,2004, 'Importance of mammalian target of rapamycin inhibitors in the prevention of cardiac allograft vasculopathy', Current Opinion in Organ Transplantation, 9, pp. 389 - 393, http://dx.doi.org/10.1097/01.mot.0000145534.54912.6f
,2004, 'Idiopathic- and scleroderma-related pulmonary arterial hypertension: Outcomes and QOL on bosentan', Expert Review of Pharmacoeconomics and Outcomes Research, 4, pp. 505 - 513, http://dx.doi.org/10.1586/14737167.4.5.505
,2004, 'Woundcare Research for Appropriate Products (WRAP): Validation of the TELER method involving users', International Journal of Nursing Studies, 41, pp. 559 - 571, http://dx.doi.org/10.1016/j.ijnurstu.2003.12.009
,2004, 'Patient and professional partnership in diabetic nephropathy', EDTNA-ERCA Journal, 30, pp. 166 - 168, http://dx.doi.org/10.1111/j.1755-6686.2004.tb00360.x
,2004, 'Calcineurin inhibitors in heart transplantation', Journal of Heart and Lung Transplantation, 23, pp. S202 - S206, http://www.sciencedirect.com/science/article/B6VSG-4C5FTMN-4/2/de9e3eb6a345a357ce626720af954589
,2004, 'Comparison and validation of three quality of life instruments for the functional assessment of pulmonary arterial hypertension', Journal of Heart and Lung Transplantation, 23, pp. S143 - S143, http://www.sciencedirect.com/science/article/B6VSG-4BJK13R-BM/2/f417d36bda8b4e9684645d30d56c574c
,2004, 'Comparison of gene expression between left atria and left ventriclesfrom non-diseased humans', Proteomics, 4, pp. 261 - 270
,2004, 'HEART TRANSPLANT PATIENTS TREATED WITH SIROLIMUS IMMMUNOTHERAPY SHOW SIGNIFICANT REDUCTION IN THE PROGRESSION OF GRAFT VASCULOPATHY AT 2 YEARS', Transplantation, 78, pp. 160 - 160, http://dx.doi.org/10.1097/00007890-200407271-00421
,2004, 'Nitric oxide pathway and phosphodiesterase inhibitors in pulmonaryarterial hypertension', Journal of the American College of Cardiology, 43, pp. 68S - 72S
,2004, 'Severe diverticulitis after heart, lung, and heart-lung transplantation', Journal of Heart and Lung Transplantation, 23, pp. 845 - 849
,2004, 'Sirolimus from the time of heart transplantation - persistent protection from graft vasculopathy at 2 years', The Journal of Heart and Lung Transplantation, 23, pp. S106 - S107, http://dx.doi.org/10.1016/j.healun.2003.11.194
,2004, 'Sirolimus in de novo heart transplant recipients reduces acuterejection and prevents coronary artery disease at 2 years - Arandomized clinical trial', Circulation, 110, pp. 2694 - 2700
,2004, 'Sirolimus provides protection from graft vasculopathy at 2 years afterheart transplantation', American Journal of Transplantation, 4, pp. 281 - 281
,2004, 'The impact of baseline left ventricular size and mitral regurgitationon reverse left ventricular remodelling in response to carvedilol: sizedoesn`t matter', Heart, 90, pp. 800 - 801
,2004, 'TRACLEER(R) (bosentan), for the treatment of pulmonary arterial hypertension (PAH) - 6 month quality of life data', Journal of Heart and Lung Transplantation, 23, pp. S54 - S54, http://www.sciencedirect.com/science/article/B6VSG-4BJK13R-18/2/c4e03edb8882660d8ad37686c58a3819
,2003, 'Cyclosporin C
2003, 'Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol', Transplantation, 75, pp. 2133 - 2134, http://dx.doi.org/10.1097/01.TP.0000065179.06731.99
,2003, 'Pulmonary arterial hypertension: A new era in management', Medical Journal of Australia, 178, pp. 564 - 567, http://dx.doi.org/10.5694/j.1326-5377.2003.tb05360.x
,2003, 'Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: A single centre, observational study', Heart, 89, pp. 293 - 298, http://dx.doi.org/10.1136/heart.89.3.293
,2003, 'Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression', Journal of Heart and Lung Transplantation, 22, pp. 1276 - 1279, http://dx.doi.org/10.1016/S1053-2498(02)01239-1
,2003, 'CHART: Congestive cardiac failure in hospitals an Australian review of treatment', Heart Lung and Circulation, 12, pp. 94 - 102, http://dx.doi.org/10.1046/j.1444-2892.2003.00197.x
,2003, 'Randomised double-blind, placebo-controlled trial of coenzyme Q
2003, 'Bosentan increases warfarin dosing requirements in pulmonary hypertension', Journal of the American College of Cardiology, 41, pp. 225 - 225, http://dx.doi.org/10.1016/S0735-1097(03)81629-7
,2003, 'Carvedilol in elderly heart failure patients', Heart, Lung and Circulation, 12, pp. 94 - 94
,2003, 'Cytomegalovirus polymerase chain reaction tests can replace endoscopy and biopsy for the initial diagnosis of cytomegalovrius gastrointestinal disease in patients following heart transplantation', CSANZ
,2003, 'Dobutamine stress echocardiography is predictive of events after heart transplantation', Journal of Heart and Lung Transplantation, 22, pp. 174 - 174
,2003, 'Efficacy, tolerability and long-term effects of carvedilol in women.', Heart, Lung and Circulation, 12, pp. 94 - 94, http://dx.doi.org/10.1046/j.1443-9506.2003.03544.x
,2003, 'Predictive factors of near normalisation of ejection fraction in patients with heart failure.', Heart, Lung and Circulation, 12, pp. 92 - 92
,2003, 'Pulmonary thromboendarterectomy in australia: Early results of the St Vincent`s programme', Thoracic Society
,2003, 'Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol', Transplantation, 75, pp. 133 - 134
,